32 - NHS-Galleri Trial: One Participant's Journey Through Early Detection

In this episode, Robert, a carpenter from the Midlands in England and a participant in the NHS-Galleri trial, joins host Shawnda Madison to share his experience. After enrolling in the trial, Robert received a Cancer Signal Detected result from the Galleri multi-cancer early detection (MCED) test despite having no symptoms. The initial diagnostic evaluation did not identify cancer, but a subsequent Galleri test the following year returned the same result, leading his care team to continue investigating. Eventually, a biopsy revealed a small HPV-related cancer at the base of his tongue. Robert reflects on the uncertainty of waiting for answers, the treatment and recovery that followed, and how the experience changed the way he thinks about health, screening, and the value of finding cancer earlier. Transcripts: https://grail.com/podcast/ Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/ The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. See Important Safety Information: https://www.galleri.com/safety-information The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV). Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.